Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

300
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
300
Clinical Trials01:16

Clinical Trials

9.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.8K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

762
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
762
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction: Interventions against disability in frail older adults: Lessons learned from clinical trials.

The journal of nutrition, health & aging·2026
Same author

Corrigendum to "Current and investigational medications for the treatment of sarcopenia" [Metabolism 2023;149:155597].

Metabolism: clinical and experimental·2026
Same author

Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2025
Same author

Editorial: ICOPE Healthy Longevity Integrative Preventive Care, Alzheimer's Disease Prevention and Early Diagnosis.

The journal of prevention of Alzheimer's disease·2024
Same author

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2024
Same author

The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohort.

Revue neurologique·2024
Same journal

Drawing a line: Differentiating mild from moderate dementia using the functional activities questionnaire.

The journal of prevention of Alzheimer's disease·2026
Same journal

The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population.

The journal of prevention of Alzheimer's disease·2026
Same journal

Asia's dementia burden: from epidemiological description to prevention-oriented neurology.

The journal of prevention of Alzheimer's disease·2026
Same journal

The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 status.

The journal of prevention of Alzheimer's disease·2026
Same journal

Beyond target engagement: RNA therapeutics and the neuroimmune challenge in tauopathies.

The journal of prevention of Alzheimer's disease·2026
Same journal

Tailored implementation of multidomain intervention to prevent cognitive impairment in community-dwelling older adults (Timi-Cog): A study protocol for a hybrid type 2 trial effectiveness-implementation study.

The journal of prevention of Alzheimer's disease·2026
See all related articles

Related Experiment Video

Updated: Oct 18, 2025

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.0K

Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force.

J Kaye1, P Aisen, R Amariglio

  • 1Jeffrey Kaye, Layton Aging and Alzheimer's Disease Center, School of Medicine, Oregon Health and Science University, Portland, OR, USA, kaye@ohsu.edu.

The Journal of Prevention of Alzheimer'S Disease
|September 29, 2021
PubMed
Summary
This summary is machine-generated.

Digital technologies offer solutions for Alzheimer's disease (AD) clinical trials disrupted by the COVID-19 pandemic. While challenges like data validity and privacy exist, further exploration and standardization are recommended for remote assessments.

Keywords:
Alzheimer’s diseaseclinical outcomesdigital toolsremote assessments

More Related Videos

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

1.5K
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

828

Related Experiment Videos

Last Updated: Oct 18, 2025

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.0K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

1.5K
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

828

Area of Science:

  • Neurology
  • Clinical Research Informatics
  • Digital Health

Background:

  • The COVID-19 pandemic significantly disrupted global Alzheimer's disease (AD) clinical studies.
  • Digital technologies present a potential solution for remote assessment of cognitive and functional changes in AD.
  • The EU/US Clinical Trials in Alzheimer's Disease (CTAD) Task Force convened to discuss digital technology integration in AD research.

Purpose of the Study:

  • To explore the opportunities and challenges of using digital technologies in Alzheimer's disease clinical research.
  • To assess the potential of digital tools to mitigate pandemic-related disruptions in AD trials.
  • To provide recommendations on the future use of digital technologies in AD clinical studies.

Main Methods:

  • Virtual meeting of the EU/US CTAD Task Force in November 2020.
  • Discussion and analysis of the benefits and drawbacks of digital technologies in AD clinical research.
  • Review of existing literature and expert opinions on digital data in clinical trials.

Main Results:

  • Digital tools can accelerate trials, enhance participant diversity, capture meaningful data, and reduce costs.
  • Concerns persist regarding the stability, validity, generalizability, and reproducibility of digital data.
  • Regulatory acceptance and data privacy remain significant challenges for digital health solutions.

Conclusions:

  • Further exploration of digital technologies through collaboration and data sharing is supported.
  • Standardization of digital readouts is crucial for reliable data collection.
  • Remote assessments may be feasible for non-invasive, multi-domain AD studies, but premature for novel medication trials.